Metalloproteinases and their endogenous inhibitors are key components of an enzyme system which is important in a number of fundamental biochemical and cellular processes. Our recent work has focused on the role of a particular metalloproteinase, collagenase, and the role of an endogenous inhibitor
A Metalloproteinase Inhibitor from Doliocarpus verruculosus
โ Scribed by Hao H. Sun; Paul V. Kaplita; David R. Houck; Mary B. Stawicki; Ruthann McGarry; Robert C. Wahl; Amanda M. Gillum; Raymond Cooper
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 334 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0951-418X
No coin nor oath required. For personal study only.
โฆ Synopsis
In our natural products screening programme for the discovery of competitive inhibitors of the matrix metalloproteinases, stromelysin and collagenase, we have isolated an active compound, betulinic acid (l), from the plant Doliocarpus uerruculosus. Betulinic acid inhibits stromelysin and collagenase with Ki values of 2.2 and 1.3 CM, respectively. The analogous C-28 alcohol, betulin, was a less potent inhibitor of these proteases. We therefore postulate that the moiety of 1-carboxyl-3-(2-propenyl)-cyclopentane in betulinic acid may mimic the hydroxamate-containing residue of actinonin (3), a known stromelysin and collagenase inhibitor. Because a hydroxamate can serve as a bidentate ligand for the active site zinc, we synthesized the hydroxamate of 3acetoxy-betulinic acid (2), hoping to observe an increase in potency relative to 1. However, the Ki values against stromelysin and collagenase were essentially equal to those of 1. These data suggest that the rigid cyclopentyl ring is probably restricting the tight binding as seen in the flexible peptidal hydroxamates, or the acid moiety is not interacting directly with the active site zinc of the metalloproteinases.
๐ SIMILAR VOLUMES
## Abstract The desire to inhibit zincโdependent matrix metalloproteinases (MMPs) has, over the course of the last 30 years, led to the development of a plethora of MMP inhibitors that bind directly to the activeโsite metal. With one exception, all of these drugs have failed in clinical trials, due